STOCK TITAN

GLAUKOS (GKOS) SEC Filings, Jun 3-23, 2026

GKOS NYSE

Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.

The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.

Rhea-AI Summary

Glaukos Corp director Mark J. Foley reported a grant of 2,987 stock options for common stock, each with an exercise price of $106.52. These options were granted under the company’s Director Compensation Policy and vest in full on the one-year anniversary of the May 28, 2026 grant date.

This Form 4/A corrects an earlier filing that mistakenly listed the exercise price as $53.57. After this grant, Foley holds 2,987 stock options from this award, which are scheduled to expire on May 28, 2036 if not exercised.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
insider
-
Rhea-AI Summary

Glaukos Corp director Leana Wen received a grant of stock options, and the amended Form 4 corrects their exercise price. On May 28, 2026 she was granted options for 2,987 shares of common stock at an exercise price of $106.52 per share, expiring on May 28, 2036. These options were granted under the company’s Director Compensation Policy and vest in full on the one-year anniversary of the grant date. After this grant, she holds 2,987 stock options directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
insider
-
Rhea-AI Summary

GLAUKOS Corp director Marc Stapley reported a grant of stock options for 2,987 shares of Common Stock. These options carry an exercise price of $106.52 per share and were granted on May 28, 2026 under the issuer's Director Compensation Policy.

The options vest in full on the one-year anniversary of the grant date and expire on May 28, 2036. This Form 4/A also corrects a prior filing that had mistakenly reported the exercise price as $53.57, confirming the correct price as $106.52.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
insider
Rhea-AI Summary

Glaukos Corp director Aimee S. Weisner received a grant of 2,987 stock options as director compensation. The options have an exercise price of $106.52 per share, were granted on May 28, 2026, and vest in full on the one-year anniversary of the grant date. They are scheduled to expire on May 28, 2036. This amended Form 4 corrects an earlier filing that had reported the exercise price incorrectly, and reflects a routine equity award rather than an open-market stock purchase or sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
insider
-
Rhea-AI Summary

GLAUKOS Corp director Gilbert H. Kliman received a grant of 2,987 stock options, each with an exercise price of $106.52. The options relate to common stock and were awarded under the company’s Director Compensation Policy as part of his board compensation.

This Form 4/A is an amendment to a prior filing that had mistakenly reported the exercise price as $53.57. The options were granted on May 28, 2026, vest in full on the one-year anniversary of the grant date, and expire on May 28, 2036.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
insider
-
Rhea-AI Summary

GLAUKOS Corp director David F. Hoffmeister received a grant of 2,987 stock options, and the company corrected the reported exercise price. The amended Form 4 updates a prior filing that mistakenly listed the strike price as $53.57; the correct exercise price is $106.52. These options, granted under the issuer’s Director Compensation Policy, vest in full on the one-year anniversary of the May 28, 2026 grant date and are exercisable until May 28, 2036, giving him the right to buy an equal number of common shares at that price.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
insider
Rhea-AI Summary

GLAUKOS Corp director Denice Torres reported a stock option grant and corrected prior disclosure details. She received options for 2,987 shares of common stock at an exercise price of $106.52 per share, granted under the issuer's Director Compensation Policy. The options vest in full on the one-year anniversary of the May 28, 2026 grant date and expire on May 28, 2036. This Form 4/A also amends a prior Form 4 that mistakenly reported the exercise price as $53.57, clarifying that the correct exercise price is $106.52.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
insider
-
Rhea-AI Summary

Glaukos Corp’s chief development officer Tomas Navratil sold 1,537 shares of common stock in an open-market trade. The sale was executed at an average price of $130.68 per share under a Rule 10b5-1 trading plan adopted on March 12, 2026.

After this transaction, he directly holds 88,833 shares of Glaukos common stock, which includes 39,791 restricted stock units that have not yet vested or been delivered.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
insider
-
Rhea-AI Summary

GLAUKOS Corp (GKOS) officer Tomas Navratil reported a planned sale of 1,537 common shares, with an aggregate market value of $200,855.16 and an approximate sale date of June 16, 2026. Acquisition entries list restricted stock vesting from the issuer on November 15, 2024, December 13, 2024, and March 24, 2025. Jennifer Ruchti signed as Fidelity Brokerage Services LLC's duly authorized representative and attorney-in-fact for Tomas Navratil.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
other
Rhea-AI Summary

Glaukos Corporation held its annual stockholder meeting and reported voting results on three proposals. Stockholders elected Class II directors Denice M. Torres and Aimee S. Weisner to serve until the 2029 annual meeting, with Weisner receiving 49,397,952 votes for and Torres 40,843,317 votes for. The advisory vote on executive compensation passed, with 47,653,794 votes for and 4,272,830 against. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 54,476,088 votes for and 515,703 against.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.08%
Tags
current report

FAQ

How many GLAUKOS (GKOS) SEC filings are available on StockTitan?

StockTitan tracks 174 SEC filings for GLAUKOS (GKOS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for GLAUKOS (GKOS)?

The most recent SEC filing for GLAUKOS (GKOS) was filed on November 20, 2026.